Hemant Surgical Industries Limited has acquired a 66.66% majority stake in Lifesenz Cancer Research Labs Private Limited for ₹19.98 Crores, effective June 01, 2026. This strategic acquisition makes Lifesenz a subsidiary of Hemant Surgical Industries , marking its entry into the precision oncology segment. The transaction aligns with the company's objective to expand beyond traditional healthcare distribution into advanced diagnostics and personalized medicine.

Lifesenz operates in precision oncology, utilizing patient-derived 3D cancer cell models for ex-vivo chemo-sensitivity analysis. This technology assists clinicians in selecting patient-specific treatments by evaluating effectiveness before therapy administration. The integration of Lifesenz's scientific capabilities with Hemant Surgical's established distribution network is expected to enhance its portfolio of differentiated healthcare solutions and strengthen relationships with hospitals and clinicians.

The Board of Directors evaluated the acquisition based on long-term strategic advantages rather than near-term profitability metrics. Management acknowledges that Lifesenz is currently in a growth and development phase, requiring investments in research and infrastructure, and will take time to break even. The acquisition was conducted on an arm's length basis to serve the best interests of the company.

Strategic Synergies and Future Outlook

The company plans to leverage its existing market reach to scale Lifesenz's operations. Key initiatives include strengthening clinical collaborations, expanding patient adoption, and increasing commercialization opportunities. Management believes that growing awareness of personalized cancer treatment will drive demand for these technologies in the coming years.

Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited, stated that the acquisition reflects the company's commitment to the future of healthcare. He emphasized that combining Lifesenz's scientific expertise with Hemant Surgical's platform creates a foundation for long-term growth and improved patient care outcomes.

Hemant Surgical Industries Limited has completed the acquisition of Lifesenz Cancer Research Labs Private Limited for ₹19,99,80,000 to expand its presence in the healthcare and cancer diagnostic support segment. The acquisition, which was approved by the board on May 27, 2026, was finalized on June 01, 2026, making Lifesenz a subsidiary of the company with effect from the same date. The deal was structured as a related party transaction, as existing shareholders and directors of the target entity are also promoters, directors, or shareholders of Hemant Surgical Industries.

The transaction involved the purchase of 6,666 equity shares representing 66.66% of the paid-up equity share capital of Lifesenz Cancer Research Labs. The consideration of ₹19,99,80,000 was paid in cash, based on a valuation report from a Registered Valuer. The company stated that the transaction was undertaken at arm's length and was subject to conditions precedent specified in the Share Purchase Agreement, which have now been satisfied.

Lifesenz Cancer Research Labs, incorporated on February 28, 2022, operates in Mumbai, Maharashtra, and is engaged in assisting clinicians and cancer patients by providing predicted therapy solutions. The entity belongs to the healthcare industry, specifically cancer research and diagnostic support services. No governmental or regulatory approvals were required for the acquisition.

The financial size of the target entity for F.Y. 24-25 indicates a turnover of ₹56.75 Lakhs, a Profit After Tax (PAT) of ₹(74.76) Lakhs, and a net worth of ₹(221.84) Lakhs. The acquisition is intended to strengthen Hemant Surgical Industries' capabilities in the cancer diagnostic support market.